TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6744203
Drug: Levamisole immunotherapy
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole immunotherapy (150 mg a day, 2 days weekly)
Study: 1564302
Drug: Acute i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute i.v. administration of erythromycin (500 mg every 8 hours for 24 hours)
Study: 1564302
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral therapy with erythromycin (500 mg three times daily for 15 weeks)
Study: 22576305
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate ointment
Study: 8964395
Drug: Budesonide 10
Normalized name: budesonide 100 MCG/ACTUAT Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 10 mg daily
Study: 30682445
Drug: Sipuleucel-T after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sipuleucel-T after sensitizing radiation therapy (Arm B)
Study: 26991468
Drug: Oral pentoxyfylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pentoxyfylline 400 mg thrice daily for 3 weeks
Study: 26991468
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet thrice daily for 3 weeks
Study: 22569029
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg kg(‐1) following remifentanil infusion at 0.5 μg kg(‐1) min(‐1)
Study: 9407256
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement (2.9 g.day-1) containing leucine, isoleucine, valine, glutamine, and carnitine
Study: 9407256
Drug: Lactose (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (3 g.day-1)
Study: 8171216
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg two times daily for 3 months
Study: 3513752
Drug: Phenmetrazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenmetrazine (25 mg)
Study: 3513752
Drug: Pemoline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (75 mg)
Study: 11491175
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment (5 days)
Study: 11491175
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (5 days)
Study: 30528698
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of RPCRC and 4Kscore
Study: 30528698
Drug: RPCRC-4Kscore combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: RPCRC-4Kscore combination
Study: 27481512
Drug: G-CSF application
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF application (yes)
Study: 27481512
Drug: G-CSF application
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF application (no)
Study: 24736628
Drug: Lobeglitazone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone 0.5 mg
Study: 19846796
Drug: Intraperitoneal open-loop
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal open-loop insulin delivery (control)
Study: 18035206
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg/d
Study: 15707858
Drug: Formoterol 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 36 microg TID via Aerolizer (total daily dose 108 microg)
Study: 15707858
Drug: Salbutamol 600
Normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salbutamol 600 microg TID via pMDI (total daily dose 1800 microg)
Study: 29550525
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS treatment (1 mA, 3 sessions per week for 6 weeks)
Study: 20015525
Drug: Sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 100 mg once a day added to pioglitazone 30 mg
Study: 20015525
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg twice a day added to pioglitazone 15 mg
Study: 8867263
Drug: Phentolamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine 0.5 mg/kg over 20 min
Study: 8867263
Drug: Phentolamine 1
Normalized name: phentolamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine 1 mg/kg over 10 min
Study: 6367617
Drug: Estradiol-17 beta
Normalized name: ESTRADIOL 17-BETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-17 beta 4 mg daily
Study: 6367617
Drug: Estradiol-17 beta
Normalized name: ESTRADIOL 17-BETA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol-17 beta 2 mg daily
Study: 26901812
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel (0, 1.25, 2.5, 5, or 10 grams daily for 16 weeks)
Study: 26901812
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel with anastrozole (suppressing conversion of androgens to estrogens)
Study: 25281437
Drug: Colloid preload
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloid preload (6% hydroxyethyl starch 130/0.4 500 mL before spinal anesthesia)
Study: 25281437
Drug: Crystalloid co-load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid co-load (Ringer's acetate solution 1000 mL administered rapidly starting with intrathecal injection)
Study: 22458343
Drug: Epidural steroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural steroid injections with local anesthetic
Study: 22458343
Drug: Epidural injections
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural injections with local anesthetic alone (Control)
Study: 20147463
Drug: Fiber-enriched meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiber-enriched meal (psyllium, 23.0 g)
Study: 12126546
Drug: Epidural 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 2% lidocaine 10 ml combined with 2.5 microg/ml of fentanyl 30 minutes before skin incision followed by 0.125% ropivacaine and 2 microg/ml fentanyl infusion at 9ml/h to the end of surgery (Group II)
Study: 12126546
Drug: Epidural 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 2% lidocaine 10 ml combined with 2.5 microg/ml of fentanyl and 0.15 mg/ml of droperidol 30 min before incision followed by 0.125% ropivacaine and 2 microg/ml fentanyl infusion at 9ml/h to the end of surgery (Group III)
Study: 10410825
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of propranolol administered IC into the treated artery during balloon inflations
Study: 10410825
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg IC propranolol
Study: 25056567
Drug: Extended-release dexmethylphenidate
Normalized name: dexmethylphenidate Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release dexmethylphenidate (d-MPH)
Study: 25056567
Drug: Extended-release mixed
Normalized name: Amphetamine Mixed Salts Extended-Release Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release mixed amphetamine salts (MAS)
Study: 19933235
Drug: Meloxicam 15
Normalized name: meloxicam 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 15 mg/day for five consecutive days
Study: 19933235
Drug: Meloxicam 30
Normalized name: meloxicam 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 30 mg/day for five consecutive days
Study: 17681986
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (Group 3)
Study: 11999639
Drug: pimobendan (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: pimobendan (1.25 or 2.5mg twice daily)
Study: 1959
Drug: Mequitazine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mequitazine (10 mg/24 hrs)
Study: 7313613
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Diazepam and 200 ppm MeCl
Study: 27516073
Drug: Stimulant dependence
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulant dependence
Study: 24457404
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg bid for 6 months
Study: 24457404
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg qd for 6 months
Study: 20880335
Drug: Weekly paclitaxel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly paclitaxel, 80 mg/m², for 12 cycles (B1) when sensitivity test positive
Study: 20880335
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (A): Weekly paclitaxel without sensitivity test
Study: 15555694
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy plus pharmacotherapy
Study: 15555694
Drug: Multifamily psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifamily psychoeducational group therapy plus pharmacotherapy
Study: 9894374
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER 2.5 mg (increased to 5 mg or 10 mg if necessary)
Study: 26255474
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (salmon calcitonin added to calcium and calcitriol)
Study: 26255474
Drug: Comprehensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive group (incrementality waist musculi dorsi function exercise added to treatment group)
Study: 23297680
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (Control)
Study: 21872139
Drug: OMT (Optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMT (Optimal Medical Treatment)
Study: 19465671
Drug: Progestelle progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progestelle progesterone cream 20 mg
Study: 19465671
Drug: Progestelle progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progestelle progesterone cream 60 mg, 40 mg, 5 mg
Study: 10431474
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of flash liberation tablet
Study: 10431474
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of freeze-dried reference tablet (lyoc)
Study: 6553504
Drug: IV infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusions of gamma‐radiation‐sterilized cells of Propionibacterium granulosum strain KP‐45
Study: 6553504
Drug: Cytostatic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytostatic drugs only (adriamycin, cyclophosphamide, and 5‐fluorouracil)
Study: 26817506
Drug: Higher-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein diet (2.4 g · kg(‐1) · d(‐1))
Study: 26817506
Drug: Lower-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-protein diet (1.2 g · kg(‐1) · d(‐1))
Study: 24629431
Drug: afoxolaner chews
Approvals — FDA: no, EMA: no, PMDA: no
Description: afoxolaner chews administered at a dosage of at least 6.3mg/kg (1×)
Study: 24629431
Drug: afoxolaner chews
Approvals — FDA: no, EMA: no, PMDA: no
Description: afoxolaner chews administered at a dosage of at least 18.9 mg/kg (3×)
Study: 24629431
Drug: afoxolaner chews
Approvals — FDA: no, EMA: no, PMDA: no
Description: afoxolaner chews administered at a dosage of at least 31.5mg/kg (5×)
Study: 10566718
Drug: Ceftriaxone 1
Normalized name: ceftriaxone 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 1 g i.v. 30 min preintervention
Study: 7049585
Drug: Meptazinol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (400 mg)
Study: 7049585
Drug: Dextropropoxyphene (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextropropoxyphene (65 mg) plus Paracetamol (650 mg)
Study: 22467013
Drug: Chemotherapy (cytostatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cytostatic and genotoxic drugs)
Study: 16116005
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (2.2 mL of 0.5% hyperbaric bupivacaine plus 0.2 mg morphine)
Study: 16116005
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (2% lidocaine with epinephrine 1:400,000, 18‐23 mL, followed by 3 mg of morphine after delivery)
Study: 10027033
Drug: (R)-ketamine 1
Normalized name: (r)-(+)-ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-ketamine 1 mg/kg (PRE group)
Study: 10027033
Drug: Saline followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline followed by (R)-ketamine 1 mg/kg (POST group)
Study: 10027033
Drug: Analgesic consumption
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic consumption at 24 h and 7 days (all groups)
Study: 1492006
Drug: ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 500 mg twice/day for 10 days
Study: 1492006
Drug: placebo twice/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice/day for 10 days
Study: 28968870
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg once daily for 4 weeks
Study: 28968870
Drug: Valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg once daily for 4 weeks
Study: 28968870
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both drugs
Study: 15248440
Drug: Acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylcysteine (600 mg in the morning and evening before examination) with intravenous saline hydration
Study: 9663358
Drug: Hylan G-F
Normalized name: hylan G-F 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hylan G-F 20 (2 mL, three intra-articular injections, 1 week apart)
Study: 9663358
Drug: Physiologic buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic buffered saline solution (2 mL, three injections at the same intervals)
Study: 9663358
Drug: Physiologic buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiologic buffered saline solution
Study: 2856597
Drug: cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 300 mg QID
Study: 2856597
Drug: cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 800 mg HS
Study: 2856597
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg HS
Study: 25705653
Drug: DBM injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBM injection (n = 14)
Study: 25705653
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment without injection (n = 15)
Study: 23159586
Drug: Brief smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief smoking cessation intervention plus nicotine replacement therapy
Study: 21176029
Drug: Uridine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uridine (2 g)
Study: 12800416
Drug: Digoxin combined
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin combined with 20 ml of Shengmai Injection (SMI)
Study: 12800416
Drug: Digoxin combined
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin combined with 40 ml of Shengmai Injection (SMI)
Study: 12800416
Drug: Digoxin combined
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin combined with 60 ml of Shengmai Injection (SMI)
Study: 12800416
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Shengmai Injection)
Study: 9002785
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Plaque Remover‐D7
Study: 9002785
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Ultra Plaque Remover‐D9
Study: 4077545
Drug: Self-Management Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Management Training Program (SCRPA) for school-age children (ages 6-14), consisting of eight 90-minute classes for both child and parent(s) scheduled twice a week for 4 weeks.
Study: 4077545
Drug: Self-Management Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-Management Training Program (SCRPA) for preschool children (ages 2-5), consisting of six 1-hour classes scheduled twice a week for 3 weeks.
Study: 31408467
Drug: Novel drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel drink powder (4 g betaine, 800 μg folic acid, 5.2 μg vitamin B12, and 2.8 mg vitamin B2)
Study: 31408467
Drug: UNIMMAP (widely
Approvals — FDA: no, EMA: no, PMDA: no
Description: UNIMMAP (widely used multiple micronutrient tablet containing 15 micronutrients)
Study: 22873117
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (control site)
Study: 22873117
Drug: Ketorolac (COX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (COX pathway inhibitor)
Study: 17259476
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g HV‐HPMC
Study: 17259476
Drug: 8 g
Normalized name: Theranost 68 Ga Rgd
DrugBank: NODAGA-THERANOST Ga-68 (DB16940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 g HV‐HPMC
Study: 17259476
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (8 g cellulose)
Study: 15734080
Drug: Amoxicillin-sulbactam
Normalized name: amoxicillin / sulbactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-sulbactam
Study: 7762842
Drug: Adenosine infusion,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine infusion, 80 micrograms.kg-1.min-1
Study: 2268865
Drug: Slow‐K (wax-matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow‐K (wax-matrix tablet)
Study: 2268865
Drug: K‐Dur (microencapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: K‐Dur (microencapsulated tablet)
Study: 78384
Drug: E. coli
Normalized name: E. coli antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: E. coli H‐10407 (C.F.A.+) at a dose of 10(8)
Study: 16306137
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol (PEG) electrolyte balanced solution, 29.5 g daily for 7 days
Study: 10786346
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac emulsion gel applied every 8 hours for 48 hours
Study: 10786346
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 75 mg p.o. every 12 hours for 48 hours
Study: 9381637
Drug: Likopide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Likopide (10 mg tablets, orally, twice daily for 3 days, followed by a 3-day interval, then 3 days of treatment)
Study: 8239057
Drug: Padma 28
Normalized name: Padma Flower
DrugBank: Nelumbo nucifera flower (DB14333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Padma 28 (340 mg, two tablets bid)
Study: 3919831
Drug: Cisplatin 120
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 120 mg intravenously
Study: 3919831
Drug: Cyclophosphamide 2
Normalized name: cyclophosphamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 2 g intravenously
Study: 27852286
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment plus extracranial-intracranial (EC-IC) bypass surgery
Study: 25130149
Drug: Low-dose hCG
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose hCG (200 IU daily)
Study: 20090953
Drug: Self-Administered Questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-Administered Questionnaire (SAQ)
Study: 17392718
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (SJW) 900 mg daily for 12 days
Study: 15629592
Drug: High-source strength
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-source strength implants (0.76 microGy/m(2)/h)
Study: 15629592
Drug: Low-source strength
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-source strength implants (0.4 microGy/m(2)/h)
Study: 15629592
Drug: High-source strength
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-source strength implants
Study: 15629592
Drug: Low-source strength
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-source strength implants
Study: 7027750
Drug: Initial dose
Normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial dose of glipizide (5 mg p.o.)
Study: 7027750
Drug: Long-term treatment
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term treatment with glipizide (range 7.5‐20 mg, mean 10.4 mg)
Study: 7027750
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose regime
Study: 7027750
Drug: Three-part divided
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-part divided dose regime